Oestrogen (adjunct) versus placebo for women with schizophrenia
dc.contributor.author | Grigorov, Hristo S. | |
dc.date.accessioned | 2017-09-20T15:57:43Z | |
dc.date.available | 2017-09-20T15:57:43Z | |
dc.date.issued | 2016 | |
dc.identifier.citation | Chua, W. L. L., Grigorov, H. S. & Hiley, J. (2016). Oestrogen (adjunct) versus placebo for women with schizophrenia. Cochrane Database of Systematic Reviews, (6), pp.14. | |
dc.identifier.other | 10.1002/14651858.CD012220 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12904/9853 | |
dc.description.abstract | This is the protocol for a review and there is no abstract. The objectives are as follows: To evaluate the clinical efficacy and safety of oestrogen as an adjunctive treatment versus placebo, in women with schizophrenia or schizophrenia-like illnesses. Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. | |
dc.description.uri | http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD012220/full | |
dc.format | Full text uploaded | |
dc.subject | Schizophrenia | |
dc.subject | Drug therapy | |
dc.title | Oestrogen (adjunct) versus placebo for women with schizophrenia | |
dc.type | Article | |
refterms.dateFOA | 2021-06-14T11:07:55Z | |
html.description.abstract | This is the protocol for a review and there is no abstract. The objectives are as follows: To evaluate the clinical efficacy and safety of oestrogen as an adjunctive treatment versus placebo, in women with schizophrenia or schizophrenia-like illnesses. Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. |